Kenneth Gordon to Prognosis
This is a "connection" page, showing publications Kenneth Gordon has written about Prognosis.
Connection Strength
0.262
-
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov; 32(11):1940-1949.
Score: 0.094
-
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. J Am Acad Dermatol. 2017 Dec; 77(6):1030-1037.
Score: 0.089
-
From laboratory to clinic: rationale for biologic therapy. Dermatol Clin. 2004 Oct; 22(4):371-7, vii-viii.
Score: 0.036
-
Evolution of biologic therapies for the treatment of psoriasis. Skinmed. 2003 Sep-Oct; 2(5):286-94.
Score: 0.034
-
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005 Jun; 141(6):683-7.
Score: 0.009